ZLCS: Zalicus Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 2, 10:56 AM Zalicus (ZLCS): Q1 EPS of -$0.06 beats by $0.01. Revenue of $3.7M beats by $0.26M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Tuesday, April 2, 8:59 AM The Patent Office grants Zalicus (ZLCS +7.6%) a patent that covers a range of compositions for, and methods of using, its Z160 drug for treating pain. The decision protects Z160 until 2032. The medicine is in two Phase IIa trials for chronic neuropathic pain. (PR) 2 Comments [Healthcare, On the Move]
Tuesday, March 19, 9:10 AM Zalicus (ZLCS +8.15%) presents preclinical data showing the advantages of applying the firm's "state dependent screening approach" in identifying novel calcium channel blockers for the treatment of pain. One such blocker, Z160, is in Phase IIa trials. It's designed for treating chronic neuropathic pain. (PR) 2 Comments [Healthcare, On the Move]
Wednesday, March 6, 1:48 PM Zalicus (ZLCS -0.5%) trades slightly lower today despite a solid Q4 earnings beat. Revenue for the quarter came in at $3.8M, up from $2.6M a year earlier. Oppenheimer reiterated its Outperform rating and $2.00 price target on the shares, saying the two ongoing Z160 Phase IIa proof-of-concept studies in chronic neuropathic pain are expected to yield encouraging top-line data by late-2H13. 4 Comments [Healthcare, Earnings]
Wednesday, March 6, 7:41 AM Zalicus (ZLCS): Q4 EPS of -$0.06 beats by $0.02. Revenue of $3.79M beats by $0.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 4, 2:59 PM Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back yesterday's +15% run after saying it's initiated the second of two Phase 2a clinical studies with Z160, its treatment for chronic neuropathic pain. Comment! [Healthcare, On the Move]
Thursday, January 3, 11:41 AM Zalicus (ZLCS +9.5%) trades up today after saying it's initiated the second of two Phase 2a clinical studies with Z160, a selective N-type calcium channel blocker designed to potentially treat chronic neuropathic pain. Comment! [Healthcare, On the Move]
Monday, September 10, 2012, 9:10 AM Premarket gainers: KSW +22%. CTIC +5%.
Losers: GERN -47%. ZLCS -46%. TITN -16%. Comment! [On the Move]
Monday, September 10, 2012, 8:09 AM Following a Phase 2b trial, Zalicus (ZLCS) says "in the absence of a clinically meaningful benefit with Synavive compared to its active glucocorticoid component, Zalicus will discontinue further clinical development with Synavive. These results are not only disappointing to Zalicus, but also to the many steroid-dependent patients who are seeking a safer treatment alternative." (PR) 1 Comment [Breaking News, Healthcare]
Monday, August 27, 2012, 12:03 PM Zalicus (ZLCS +11.1%) takes off after announcing the FDA has approved the sale of 32mg tablets for Covidien's (COV +0.6%) Exalgo pain-relief drug. The sale of 8, 12, and 16mg tablets was approved in 2010. Zalicus receives royalties on Exalgo sakes. (PR) 2 Comments [Healthcare, On the Move]
Monday, August 27, 2012, 9:10 AM Premarket gainers: KNXA +41%. ZLCS +23%. HTZ +16%. HCBK +14%. IMGN +13%. NOK +9%. SRPT +8%. DTG +7%. NAV +7%. MTSL +7%. TIF +6%. RIMM +5%. CAR +5%.
Losers: IDIX -17%. VRNG -6%. PPHM -6%. 1 Comment [On the Move]
Thursday, August 9, 2012, 9:10 AM Premarket gainers: RBN +27%. RDEN +17%. MDRX +17%. JRCC +11%. PSTI +7%. PHMD +7%. ZLCS +6%. AEG +6%. NOK +6%. EAT +5%.
Losers: MATR -9%. MNST -7%. QCOR -7%. 1 Comment [On the Move]
Tuesday, August 7, 2012, 9:49 AM More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis (NVS), "validating the value" of Zalicus' cHTS technology for developing cancer treatments. Zalicus is also on track to start Phase 2a trials of Z160, a drug for neuropathic pain, and to report results of a Phase IIb trial for Synavive, which is used for rheumatoid arthritis. (PR) Comment! [On the Move, Healthcare]
Tuesday, August 7, 2012, 9:17 AM Zalicus (ZLCS): Q2 EPS of -$0.09 beats by $0.02. Revenue of $2.9M (+58% Y/Y) beats by $0.3M. Shares +8.9% premarket. (PR) Comment! [Healthcare, On the Move]
Tuesday, August 7, 2012, 9:10 AM Premarket gainers: USHS +37%. BSFT +24%. FOSL +21%. LOPE +18%. BVSN +10%. ZLCS +10%. VRNG +9%. IHG +8%. CIM +6%. NOK +6%. MGM +5%. DCTH +5%.
Losers: WMS -20%. LEAP -18%. NIHD -16%. ELN -11%. CORT -10%. HEK -9%. DUF -8%. Comment! [On the Move]
Tuesday, July 31, 2012, 9:39 AM Zalicus (ZLCS +6.6%) shoots higher at the open after a glowing writeup from blogger Ramsay Schrum. ZLCS' Z160 & Z944 calcium channel blockers have the potential to create the first pain management drug that is orally administered without the abuse and addictive side effects that come with the use of opioids, Schrum writes. Comment! [Healthcare, Quick Ideas, On the Move]

ZLCS Zalicus Inc.

ZLCS

Zalicus Inc.